Company Release no. 23/2018
To: NASDAQ Copenhagen A/S
Copenhagen, Denmark, 28 December 2018
Veloxis Pharmaceuticals Announces Financial Calendar for 2019
Veloxis Pharmaceuticals A/S (OMX: VELO) today announced its financial calendar for 2019.
The full updated calendar is shown below.
| 19 February 2019: | Deadline for Veloxis’s Receipt of Shareholder Proposals for the 2019 Annual General Meeting. | |
| 27 February 2019: | Release of 2018 Annual Report. | |
| 3 April 2019: | 2019 Annual General Meeting. | |
| 6 May 2019: | Q1 Interim Report – for the period 1 January to 31 March, 2019. | |
| 8 August 2019: | Q2 Interim Report – for the period 1 January to 30 June, 2019. | |
| 12 November 2019: | Q3 Interim Report – for the period 1 January to 30 September, 2019. |
For more information, please contact:
| Craig A. Collard President & CEO Phone: +1 919 591 3090 Email: cac@veloxis.com | Ira Duarte CFO Phone: +1 919 591 3090 Email: idu@veloxis.com |
About Veloxis Pharmaceuticals
Veloxis Pharmaceuticals A/S is a commercial-stage specialty pharmaceutical company committed to improving the lives of transplant patients. A Danish company, Veloxis Pharmaceuticals A/S operates in the U.S. through Veloxis Pharmaceuticals Inc., a wholly-owned subsidiary headquartered in Cary, North Carolina, USA and maintains a second corporate office in Edison, New Jersey, USA. Veloxis has successfully developed Envarsus XR (tacrolimus extended-release tablets) based upon the company's unique and patented delivery technology, MeltDose®, which is designed to enhance the absorption and bioavailability of select orally administered drugs. The company is focused on the direct commercialization of Envarsus XR in the US, expansion of partnerships for markets around the world, and acquisition of assets utilized in transplant patients and by adjacent medical specialties. Veloxis is listed on the NASDAQ OMX Copenhagen under the trading symbol OMX: VELO.
For further information, please visit www.veloxis.com.
Attachment
